Provided By GlobeNewswire
Last update: May 20, 2025
BURLINGTON, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today provides business updates for the First Quarter of 2025.
Read more at globenewswire.comNASDAQ:NEUP (12/12/2025, 4:30:02 PM)
4.08
+0.1 (+2.51%)
Find more stocks in the Stock Screener


